{
  "list": [
    {
      "id": "chads2-score-for-atrial-fibrillation",
      "title": "CHADS2 Score for Atrial Fibrillation"
    },
    {
      "id": "curb-65-pneumonia-severity-score",
      "title": "CURB-65 Pneumonia Severity Score"
    },
    {
      "id": "ransons-criteria-for-pancreatitis-mortality",
      "title": "Ranson's Criteria for Pancreatitis Mortality"
    },
    {
      "id": "amoxicillin-pediatric-ear-nose-throat",
      "title": "Amoxicillin Pediatric - Ear, Nose, & Throat Infections"
    },
    {
      "id": "atrial-fibrillation-cha2ds2-vasc-score-for-stroke-risk",
      "title": "Atrial Fibrillation CHA2DS2-VASc Score for Stroke Risk"
    },
    {
      "id": "glasgow-coma-scale",
      "title": "Glasgow Coma Scale"
    }
  ],
  "calculators": [
    {
      "id": "chads2-score-for-atrial-fibrillation",
      "title": "CHADS2 Score for Atrial Fibrillation",
      "type": "points",
      "points": 0,
      "questions": [
        {
          "group": "Congestive Heart Failure History",
          "data": {
            "type": "radio",
            "options": "No/Yes",
            "points": "0/1"
          }
        },
        {
          "group": "Hypertension history",
          "data": {
            "type": "radio",
            "options": "No/Yes",
            "points": "0/1"
          }
        },
        {
          "group": "Age ≥ 75 years",
          "data": {
            "type": "radio",
            "options": "No/Yes",
            "points": "0/1"
          }
        },
        {
          "group": "Diabetes melitus history",
          "data": {
            "type": "radio",
            "options": "No/Yes",
            "points": "0/1"
          }
        },
        {
          "group": "Stroke or TIA symptoms previously",
          "data": {
            "type": "radio",
            "options": "No/Yes",
            "points": "0/2"
          }
        }
      ],
      "results": {
        "0": [
          "Low risk of thromboembolic event. 1.9% risk of event per year if no coumadin.",
          "The adjusted stroke rate was the expected stroke rate per 100 person-years derived from the multivariable model assuming that aspirin was not taken."
        ],
        "1": [
          "Intermediate risk of thromboembolic event. 2.8% risk of event per year if no coumadin.",
          "The adjusted stroke rate was the expected stroke rate per 100 person-years derived from the multivariable model assuming that aspirin was not taken."
        ],
        "2": [
          "Intermediate risk of thromboembolic event. 4.0% risk of event per year if no coumadin.",
          "The adjusted stroke rate was the expected stroke rate per 100 person-years derived from the multivariable model assuming that aspirin was not taken."
        ],
        "3": [
          "High risk of thromboembolic event. 5.9% risk of event per year if no coumadin.",
          "The adjusted stroke rate was the expected stroke rate per 100 person-years derived from the multivariable model assuming that aspirin was not taken."
        ],
        "4": [
          "High risk of thromboembolic event. 8.5% risk of event per year if no coumadin.",
          "The adjusted stroke rate was the expected stroke rate per 100 person-years derived from the multivariable model assuming that aspirin was not taken."
        ],
        "5": [
          "Note: While history of stroke provides 2 points, most physicians would move these patients directly to the high risk group (>8.5% risk of event per year if no coumadin.)",
          "By points directly: High risk of thromboembolic event. 12.5% risk of event per year if no coumadin.",
          "The adjusted stroke rate was the expected stroke rate per 100 person-years derived from the multivariable model assuming that aspirin was not taken."
        ],
        "6": [
          "Note: While history of stroke provides 2 points, most physicians would move these patients directly to the high risk group (>8.5% risk of event per year if no coumadin.)",
          "By points directly: High risk of thromboembolic event. 18.2% risk of event per year if no coumadin.",
          "The adjusted stroke rate was the expected stroke rate per 100 person-years derived from the multivariable model assuming that aspirin was not taken."
        ]
      },
      "notes": {
        "type": "unordered-list",
        "content": [
          "Estimates stroke risk in patients with atrial fibrillation",
          "The CHADS2 score is one of several risk stratification schemes that can help determine the 1 year risk of an ischemic stroke in a non-anticoagulated patient with non-valvular atrial fibrillation and determine which antithrombotic therapy is most appropriate",
          "The CHA2-DS2-VASC score may be a better tool to assess stroke risk in patients with atrial fibrillation.  It risk stratifies these patients better than the CHADS2 score"
        ]
      },
      "references": {
        "type": "ordered-list",
        "content": [
          "Gage BF, Waterman AD, Shannon W, et. al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001 Jun 13;285(22):2864-70.",
          "Go AS, Hylek EM, Chang Y, et. al. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice?. JAMA. 2003 Nov 26;290(20):2685-92."
        ]
      }
    },
    {
      "id": "curb-65-pneumonia-severity-score",
      "title": "CURB-65 Pneumonia Severity Score",
      "type": "points",
      "points": 0,
      "questions": [
        {
          "group": "Criteria",
          "data": [
            {
              "type": "checkbox",
              "label": "Confusion (abbreviated Mental Test Score <=8)",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "Urea (BUN > 19 mg/dL or 7 mmol/L)",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "Respiratory Rate > 30 per minute",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "Blood Pressure: diastolic < 60 or systeolic < 90 mmHg",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "Age >= 65 years",
              "points": "1"
            }
          ]
        }
      ],
      "results": {
        "0": [
          "Low risk group: 0.6% 30-day mortality.",
          "Consider outpatient treatment."
        ],
        "1": [
          "Low risk group: 2.7% 30-day mortality.",
          "Consider outpatient treatment."
        ],
        "2": [
          "Moderate risk group: 6.8% 30-day mortality.",
          "Consider inpatient treatment or outpatient with close followup."
        ],
        "3": [
          "Severe risk group: 14.0% 30-day mortality.",
          "Consider inpatient treatment with possible intensive care admission."
        ],
        "4": [
          "Highest risk group: 27.8% 30-day mortality.",
          "Consider inpatient treatment with possible intensive care admission."
        ],
        "5": [
          "Highest risk group: 27.8% 30-day mortality.",
          "Consider inpatient treatment with possible intensive care admission."
        ]
      },
      "notes": {
        "type": "unordered-list",
        "content": [
          "CURB-65 estimates the mortality of community-acquired pneumonia to help determine inpatient vs outpatient treatment",
          "Compared to the Pneumonia Severity Index (PSI), CURB-65 offers equal sensitivity of mortality prediction due to community-acquired pneumonia.  In fact, CURB-65 has a higher specificity than PSI"
        ]
      },
      "references": {
        "type": "ordered-list",
        "content": [
          "Lim WS, van der Eerden MM, Laing R, et. al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003 May;58(5):377-82.",
          "Lim WS, Macfarlane JT, Boswell TC, et. al. Study of community acquired pneumonia aetiology (SCAPA) in adults admitted to hospital: implications for management guidelines. Thorax. 2001 Apr;56(4):296-301."
        ]
      }
    },
    {
      "id": "ransons-criteria-for-pancreatitis-mortality",
      "title": "Ranson's Criteria for Pancreatitis Mortality",
      "type": "points",
      "points": 0,
      "questions": [
        {
          "group": "Criteria at time of patient admission to hospital",
          "data": [
            {
              "type": "checkbox",
              "label": "Age > 55",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "Glucose >200 mg/dL (>10 mmol/L)",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "WBC > 16,000",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "AST > 250",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "LDH > 350",
              "points": "1"
            }
          ]
        },
        {
          "group": "Criteria that may develop over the first 2 hospital days",
          "data": [
            {
              "type": "checkbox",
              "label": "Hct drop >10% from admission",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "BUN increase >5 mg/dL (>1.79 mmol/L) from admission",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "Ca <8 mg/dL (<2 mmol/L) within 48 hours",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "Arterial pO2 <60 mmHg within 48 hours",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "Base deficit (24 - HCO3) >4 mg/dL within 48 hours",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "Fluid needs > 6L within 48 hours",
              "points": "1"
            }
          ]
        }
      ],
      "results": {
        "0": [
          "Mortality is 1%"
        ],
        "1": [
          "Mortality is 1%"
        ],
        "2": [
          "Mortality is 1%"
        ],
        "3": [
          "Mortality is 16%"
        ],
        "4": [
          "Mortality is 16%"
        ],
        "5": [
          "Mortality is 40%"
        ],
        "6": [
          "Mortality is 40%"
        ],
        "7": [
          "Mortality is almost 100%"
        ],
        "8": [
          "Mortality is almost 100%"
        ],
        "9": [
          "Mortality is almost 100%"
        ],
        "10": [
          "Mortality is almost 100%"
        ],
        "11": [
          "Mortality is almost 100%"
        ]
      },
      "notes": {
        "type": "unordered-list",
        "content": [
          "Estimates mortality of patients with pancreatitis based on initial and 48 hour lab values",
          "The BISAP score is another alternative to estimate pancreatitis mortality with fewer variables that is as accurate"
        ]
      },
      "references": {
        "type": "ordered-list",
        "content": [
          "Ranson JH, Rifkind KM, Turner JW. Prognostic signs and nonoperative peritoneal lavage in acute pancreatitis. Surg Gyne Ob. 143:209, 1976."
        ]
      }
    },
    {
      "id": "amoxicillin-pediatric-ear-nose-throat",
      "title": "Amoxicillin Pediatric - Ear, Nose, & Throat Infections",
      "type": "formula",
      "info": {
        "drugName": "Amoxicillin",
        "drugIndication": "Ear, Nose & Throat Infections | Pediatric",
        "drugDosageInformation": [
          {
            "title": "Mild to Moderate infections",
            "content": [
              "<3 months: ≤30mg/kg/day PO divided q12hr for 48-72 hours; for ≥10 days for S pyogenes infections",
              ">3 months and <40kg: 25mg/kg/day PO divided q12 hr or 20mg/kg/day divided q8hr",
              ">40kg: 500 mg PO q12hr or 250 mg PO q8hr for 10-14 days"
            ]
          },
          {
            "title": "Severe Infections",
            "content": [
              "<3 months: ≤30mg/kg/day PO divided q12hr for 48-72 hours; for ≥10 days for S pyogenes infections",
              ">3 months and <40kg: 45mg/kg/day PO divided q12 hr or 40mg/kg/day PO divided q8hr",
              ">40kg: 500 mg PO q12hr or 250 mg PO q8hr for 10-14 days"
            ]
          },
          {
            "title": "Tonsilitis/Streptococcal pharyngitis",
            "content": [
              "50mg/kg PO qDay for 10 days, not to exceed 1g/day, or 25mg/kg PO BID for 10 days, not to exceed 500mg/dose",
              ">12 years: 775 mg PO qDay for 10days, taken within 1 hour after meal (swallow tablet whole; do not crush or chew)"
            ]
          }
        ]
      },
      "points": 0,
      "questions": [
        {
          "group": "Dosage",
          "data": [
            {
              "type": "input/select",
              "placeholder": "Enter drug dose",
              "values": [
                "mg/kg",
                "gm/kg",
                "mcg/kg"
              ]
            }
          ]
        },
        {
          "group": "Weight",
          "data": [
            {
              "type": "input/select",
              "placeholder": "Enter patient weight",
              "values": [
                "kg",
                "lbs"
              ]
            }
          ]
        },
        {
          "group": "Liquid Formulation (optional)",
          "data": [
            {
              "type": "input/select",
              "placeholder": "Enter medication amount",
              "values": [
                "mg",
                "gm",
                "mcg"
              ]
            }
          ]
        },
        {
          "group": "Per Volume",
          "data": [
            {
              "type": "input/select",
              "placeholder": "Enter medication volume",
              "values": [
                "ml",
                "L"
              ]
            }
          ]
        }
      ],
      "results": {
        "0": [
          "Mortality is 1%"
        ],
        "1": [
          "Mortality is 1%"
        ],
        "2": [
          "Mortality is 1%"
        ],
        "3": [
          "Mortality is 16%"
        ],
        "4": [
          "Mortality is 16%"
        ],
        "5": [
          "Mortality is 40%"
        ],
        "6": [
          "Mortality is 40%"
        ],
        "7": [
          "Mortality is almost 100%"
        ],
        "8": [
          "Mortality is almost 100%"
        ],
        "9": [
          "Mortality is almost 100%"
        ],
        "10": [
          "Mortality is almost 100%"
        ],
        "11": [
          "Mortality is almost 100%"
        ]
      },
      "notes": {
        "type": "unordered-list",
        "content": [
          "Estimates mortality of patients with pancreatitis based on initial and 48 hour lab values",
          "The BISAP score is another alternative to estimate pancreatitis mortality with fewer variables that is as accurate"
        ]
      },
      "references": {
        "type": "ordered-list",
        "content": [
          "Ranson JH, Rifkind KM, Turner JW. Prognostic signs and nonoperative peritoneal lavage in acute pancreatitis. Surg Gyne Ob. 143:209, 1976."
        ]
      }
    },
    {
      "id": "atrial-fibrillation-cha2ds2-vasc-score-for-stroke-risk",
      "title": "Atrial Fibrillation CHA2DS2-VASc Score for Stroke Risk",
      "type": "points",
      "points": 0,
      "questions": [
        {
          "group": "Clinical Features",
          "data": [
            {
              "type": "checkbox",
              "label": "Congestive heart failure / LV dysfunction",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "Hypertension",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "Diabetes Mellitus",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "History of stroke, TIA or thromboembolism",
              "points": "2"
            },
            {
              "type": "checkbox",
              "label": "Vascular disese (history of MI, PVD or aortic atherosclerosis)",
              "points": "1"
            }
          ]
        },
        {
          "group": "Age",
          "data": {
            "type": "radio",
            "options": "65-74 years old/>= 75 years old",
            "points": "1/2"
          }
        },
        {
          "group": "Sex",
          "data": {
            "type": "radio",
            "options": "Male/Female",
            "points": "0/1"
          }
        }
      ],
      "results": {},
      "notes": {
        "type": "unordered-list",
        "content": [
          "The Lip-Halperin article seeks to improve stroke risk stratification of the CHADS(2) score by adding more points for age >=75 and Vascular disease.",
          "The article suggests aspirin or no treatment for a score of 0, and oral anticoagulation when the score is 2 or greater."
        ]
      },
      "references": {
        "type": "ordered-list",
        "content": [
          "Lip GY, Halperin JL. Improving stroke risk stratification in atrial fibrillation. Am J Med. 2010 Jun;123(6):484-8. Review."
        ]
      }
    },
    {
      "id": "glasgow-coma-scale",
      "title": "Glasgow Coma Scale",
      "type": "points",
      "points": 0,
      "questions": [
        {
          "group": "Eye Opening",
          "data": {
            "type": "radio",
            "options": "Spontaneous/To verbal command/To pain/None",
            "points": "4/3/2/1"
          }
        },
        {
          "group": "Best Motor Response",
          "data": {
            "type": "radio",
            "options": "Obeys verbal command/Localizes painful stimuli/Flexion withdrawl from painful stimuli/Decorticate response to painful stimuli/Decerebrate response to painful stimuli/None",
            "points": "6/5/4/3/2/1"
          }
        },
        {
          "group": "Best Verbal Response",
          "data": {
            "type": "radio",
            "options": "Oriented conversation/Disoriented conversation/Inappropriate words/Incomprehensible words/Incomprehensible sounds/None",
            "points": "5/4/3/4/2/1"
          }
        }
      ],
      "results": {
        "3": ["Abnormal"],
        "4": ["Abnormal"],
        "5": ["Abnormal"],
        "6": ["Abnormal"],
        "7": ["Abnormal"],
        "8": ["Abnormal"],
        "9": ["Abnormal"],
        "10": ["Abnormal"],
        "11": ["Abnormal"],
        "12": ["Abnormal"],
        "13": ["Abnormal"],
        "14": ["Abnormal"],
        "15": ["Normal"]
      },
      "notes": {
        "type": "unordered-list",
        "content": [
          "Glasgow Coma Scale (GCS) estimates the coma severity based on Eye, Verbal and Motor criteria.",
          "The GCS is the standard used in the pre-hospital and acute care setting to evaluate for mental status assessment in both traumatic and non-traumatic presentations."
        ]
      },
      "references": {
        "type": "ordered-list",
        "content": [
          "Teasdale G, Jennett B. Assessment of coma and impaired conciousness: a practical scale. Lancet. 1974; 2:81-84."
        ]
      }
    },
    {
      "id": "apgar-score",
      "title": "Apgar Score",
      "type": "points",
      "points": 0,
      "questions": [
        {
          "group": "Strength and regularity of heart rate",
          "data": {
            "type": "radio",
            "options": "100 beats per minute or more/Less than 100/None",
            "points": "2/1/0"
          }
        },
        {
          "group": "Lung maturity",
          "data": {
            "type": "radio",
            "options": "Regular breathing/Irregular/None",
            "points": "2/1/0"
          }
        },
        {
          "group": "Muscle tone and movement",
          "data": {
            "type": "radio",
            "options": "Active/Moderate/Inappropriate words/Limp",
            "points": "2/1/0"
          }
        },
        {
          "group": "Skin color / oxygenation",
          "data": {
            "type": "radio",
            "options": "Pink/Bluish extremeties/Totally blue",
            "points": "2/1/0"
          }
        }
      ],
      "results": {
        "3": ["Abnormal"],
        "4": ["Abnormal"],
        "5": ["Abnormal"],
        "6": ["Abnormal"],
        "7": ["Abnormal"],
        "8": ["Abnormal"],
        "9": ["Abnormal"],
        "10": ["Abnormal"],
        "11": ["Abnormal"],
        "12": ["Abnormal"],
        "13": ["Abnormal"],
        "14": ["Abnormal"],
        "15": ["Normal"]
      },
      "notes": {
        "type": "unordered-list",
        "content": [
          "Glasgow Coma Scale (GCS) estimates the coma severity based on Eye, Verbal and Motor criteria.",
          "The GCS is the standard used in the pre-hospital and acute care setting to evaluate for mental status assessment in both traumatic and non-traumatic presentations."
        ]
      },
      "references": {
        "type": "ordered-list",
        "content": [
          "Teasdale G, Jennett B. Assessment of coma and impaired conciousness: a practical scale. Lancet. 1974; 2:81-84."
        ]
      }
    }
  ]
}
